Pitavastatin Further Decreases Serum High-Sensitive C-Reactive Protein Levels in Hypertensive Patients with Hypercholesterolemia Treated with Angiotensin II, Type-1 Receptor Antagonists-Reference-Cited by-同舟云学术

Pitavastatin Further Decreases Serum High-Sensitive C-Reactive Protein Levels in Hypertensive Patients with Hypercholesterolemia Treated with Angiotensin II, Type-1 Receptor Antagonists

Published:2010-10 Issue:6 Volume:32 Page:341-346
ISSN:1064-1963
Container-title:Clinical and Experimental Hypertension
language:en
Short-container-title:Clinical and Experimental Hypertension

Author:

Yoshika Masamichi,Komiyama Yutaka,Masuda Midori,Yokoi Toyohiko,Masaki Hiroya,Ohkura Hiroe,Takahashi Hakuo

Publisher

Informa UK Limited

Subject

General Medicine,Physiology,Internal Medicine

Link

http://www.tandfonline.com/doi/pdf/10.3109/10641961003628460

Reference31 articles.

1. Current Status of Lipid Management of Hypertensive Patients

2. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial

3. The pathogenesis of atherosclerosis: a perspective for the 1990s

4. Early Statin Treatment in Patients With Acute Coronary Syndrome

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Repurposing Pitavastatin and L-Glutamine: Replenishing β-Cells in Hyperlipidemic Type 2 Diabetes Mouse Model;Life;2023-04-01

2. Repurposing statin and L-glutamine: replenishing β-cells in hyperlipidemic T2D mouse model;2021-04-22

3. Pitavastatin for lowering lipids;Cochrane Database of Systematic Reviews;2020-06-19

4. A Multi-Center, Open-Label, Two-Arm Parallel Group Non-inferiority Randomized Controlled Trial Evaluating the Effect of Pitavastatin, Compared to Atorvastatin, on Glucose Metabolism in Prediabetics with Hypertension and Dyslipidemia: Rationale and Design for the China Hemoglobin A1c Metabolism Protection Union Study (CAMPUS);Cardiovascular Drugs and Therapy;2018-09-05